From K Street to Wall Street
This article was originally published in RPM Report
The Pharmaceutical Research & Manufacturers of America spends a lot of time lobbying for drug interests and trying to improve the industry's public relations image. But how much of what PhRMA does impacts individual drug company stock prices? The answer, according to top prescription drug analysts, is not much.
You may also be interested in...
The Institute of Medicine report on drug safety has put the focus directly on the Food and Drug Administration. Out of the spotlight, Big Pharma's image is recuperating. It won't last long though.
As the Medicare drug benefit gets underway in January 2006, Wall Street analysts will be looking at one metric to gauge the program's success: the number of patients that voluntarily enroll in a stand-alone drug plan. And the early numbers are not promising. Just 1 million patients enrolled in a PDP ahead of the benefit's official kick-off. Pharma needs Part D to succeed: a failure could lead to price controls.
If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.